Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MANBA | O00462 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SLC5A2 | P31639 | 8/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 3/20 | 0.32 |
| ▸ | OGA | O60502 | 2/20 | 0.32 |
| ▸ | PYGB | P11216 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15437782 | 1.00 | MANBA (0.37) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL15437548 | 0.82 | LGALS1 (0.45) | MANBALMNATHRBHIF1APYGB | |
| SCHEMBL10408361 | 0.80 | LGALS1 (0.42) | MANBALMNATHRBHIF1APYGB | |
| SCHEMBL13750573 | 0.79 | FYN (0.32) | — | |
| SCHEMBL9126858 | 0.77 | LMNA (0.39) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL28578027 | 0.76 | OGA (0.43) | OGAPYGB | |
| Hydrochloric Acid SCHEMBL9125282 | 0.76 | MANBA (0.38) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL24066047 | 0.75 | MANBA (0.40) | MANBALMNATHRBHIF1ASLC5A2 | |
| SCHEMBL15966426 | 0.75 | MANBA (0.40) | MANBALMNATHRBHIF1ASLC5A2 | |
| Beta-D-Glucose SCHEMBL29038260 | 0.74 | LGALS1 (0.41) | MANBALMNATHRBHIF1APYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024576-A1 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | LABORATOIRE BIODIM (FR) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024576-A1 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | GALE, G6PD, UGDH | MANBA 46/4885LMNA 4507/4885THRB 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.